

Biovica receives patent approval

Uppsala, Sweden, April 1, 2019. Biovica receives an additional patent on the US market for the company PCR-based product.

The patent is a kit-patent that protects against competing companies making copies of Biovica's product. The patent complements previous patent on the US market, which protects the method for the analysis, making the protection even stronger. The patent is valid until May 2031.

“It is important for Biovica to protect our unique technology. Hence, it is very positive that we now strengthen our patent protection on our most important market.”, says Anders Rylander, CEO Biovica.

Contact

Anders Rylander, CEO Biovica.

Phone: +46 (0)18 444 48 35,

E-mail: anders.rylander@biovica.com

Biovica – Best Possible Treatment from Day One.

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company's DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality. Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE labelled and MPA registered. Appointed Certified Adviser is FNCA Sweden AB, info@fnca.se, +46 8 528 00 399.

Webb www.biovica.com

Contact info@biovica.com